Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy
Netupitant/Palonosetron for the Prevention of Nausea and Vomiting Induced by Antibody-Drug Conjugate Therapy in Breast Cancer: A Randomized, Multicenter, Exploratory Phase II Study
Netupitant/Palonosetron for Prevention of Nausea and Vomiting in Breast Cancer ADC Therapy
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Jian Zhang, MD, PhD
- Numero di telefono: 85000 +8664175590
- Email: syner2000@163.com
Backup dei contatti dello studio
- Nome: Yanchun Meng, MD
- Numero di telefono: 63028 +8664175590
- Email: ycmclinicaltrials@126.com
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Age ≥ 18 years. Histologically or cytologically confirmed breast cancer. Planned to initially receive one of the following antibody-drug conjugate (ADC) agents: trastuzumab deruxtecan (T-DXd), trastuzumab rezetecan (SHR-A1811), or datopotamab deruxtecan (Dato-DXd).
Planned to use netupitant/palonosetron capsules (NEPA) prophylactically as an antiemetic prior to ADC therapy.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Expected survival ≥ 3 months.
Adequate organ function, defined as:
Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Platelet count ≥ 100 × 10⁹/L; Hemoglobin ≥ 90 g/L; Serum total bilirubin ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN (≤ 5 × ULN for patients with liver metastases); Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 60 mL/min. Able to understand and voluntarily sign written informed consent. Able and willing to use an electronic patient-reported outcome (ePRO) device to complete daily diary records.
Exclusion Criteria:
- Currently participating in another clinical trial that may affect the antiemetic evaluation or drug exposure of this study.
Nausea (Visual Analog Scale [VAS] ≥ 5 mm) or vomiting within 24 hours prior to enrollment.
Use of any antiemetic medication within 2 weeks prior to enrollment, including 5-HT3 receptor antagonists, NK1 receptor antagonists, glucocorticoids, metoclopramide, olanzapine, etc.
Use of benzodiazepines, opioids, or opioid-like medications within 1 week prior to enrollment or planned use during the study period (especially the Day 1-21 observation window), except single doses of midazolam, temazepam, or triazolam.
Known allergy to netupitant, palonosetron, or excipients of the NEPA capsule. Symptomatic brain metastases or leptomeningeal metastases (patients who have received treatment and been stable for ≥ 4 weeks are eligible).
Uncontrolled serious medical conditions, including but not limited to: uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg), uncontrolled diabetes (HbA1c ≥ 8.0%), New York Heart Association (NYHA) functional classification ≥ III, myocardial infarction or unstable angina within 6 months, or history of clinically significant QT interval prolongation.
Psychiatric disorder or cognitive impairment that may affect the reliability of nausea/vomiting assessment or ePRO completion.
Pregnant or lactating women. Any other condition that, in the investigator's judgment, makes the participant unsuitable for this study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Comparatore attivo: Standard (No Extended NEPA)
Standard antiemetic regimen consisting of netupitant/palonosetron (NEPA), dexamethasone, and olanzapine administered on Days 1-4 (Day 5: observation only). No extended NEPA dosing is given from Day 6 through Day 21. |
Oral fixed-dose netupitant/palonosetron (NEPA) capsule (300 mg netupitant / 0.5 mg palonosetron), 1 capsule administered orally. Dexamethasone 12 mg administered orally or intravenously on Day 1, , followed by 8 mg orally or intravenously once daily on Days 2-4. No dexamethasone is administered on Day 5 or during Days 6-21. Olanzapine 5 mg administered orally once daily on Days 1-4. No olanzapine is administered on Day 5 or during Days 6-21. |
|
Sperimentale: Extended NEPA (3 Boosts)
Standard antiemetic regimen (NEPA + dexamethasone + olanzapine) on Days 1-4, plus one additional NEPA capsule (netupitant 300 mg/palonosetron 0.5 mg, PO) on each of Days 6, 11, and 16. |
Oral fixed-dose netupitant/palonosetron (NEPA) capsule (300 mg netupitant / 0.5 mg palonosetron), 1 capsule administered orally. Dexamethasone 12 mg administered orally or intravenously on Day 1, , followed by 8 mg orally or intravenously once daily on Days 2-4. No dexamethasone is administered on Day 5 or during Days 6-21. Olanzapine 5 mg administered orally once daily on Days 1-4. No olanzapine is administered on Day 5 or during Days 6-21. |
|
Sperimentale: Extended NEPA (2 Boosts)
Standard antiemetic regimen (NEPA + dexamethasone + olanzapine) on Days 1-4, plus one additional NEPA capsule (netupitant 300 mg/palonosetron 0.5 mg, PO) on each of Days 6 and 13. |
Oral fixed-dose netupitant/palonosetron (NEPA) capsule (300 mg netupitant / 0.5 mg palonosetron), 1 capsule administered orally. Dexamethasone 12 mg administered orally or intravenously on Day 1, , followed by 8 mg orally or intravenously once daily on Days 2-4. No dexamethasone is administered on Day 5 or during Days 6-21. Olanzapine 5 mg administered orally once daily on Days 1-4. No olanzapine is administered on Day 5 or during Days 6-21. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Participants with No Nausea (VAS < 5 mm) During the 120-504 Hour Window After ADC Administration
Lasso di tempo: 120 to 504 hours (Days 6-21) after ADC administration
|
The no-nausea rate, defined as the proportion of participants with a Visual Analog Scale (VAS) nausea score < 5 mm, assessed during the 120-504 hour window (Days 6-21) following ADC (trastuzumab deruxtecan, trastuzumab rezetecan [SHR-A1811], or datopotamab deruxtecan) administration. |
120 to 504 hours (Days 6-21) after ADC administration
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Participants with No Significant Nausea (VAS < 25 mm) During the 120-504 Hour Window
Lasso di tempo: 120-504 hours (Days 6-21) after ADC administration
|
Proportion of participants with a VAS nausea score < 25 mm during the 120-504 hour window after ADC administration. |
120-504 hours (Days 6-21) after ADC administration
|
|
Percentage of Participants with No Vomiting During the 120-504 Hour Window
Lasso di tempo: 120-504 hours (Days 6-21) after ADC administration
|
Proportion of participants who did not experience vomiting during the 120-504 hour window after ADC administration. |
120-504 hours (Days 6-21) after ADC administration
|
|
Complete Response (CR) Rate During the 120-504 Hour Window
Lasso di tempo: 120-504 hours (Days 6-21) after ADC administration
|
Proportion of participants achieving complete response, defined as no vomiting and no use of rescue medication, during the 120-504 hour window. (Definitions per protocol.) |
120-504 hours (Days 6-21) after ADC administration
|
|
Complete Protection (CP) Rate During the 120-504 Hour Window
Lasso di tempo: 120-504 hours (Days 6-21) after ADC administration
|
Proportion of participants achieving complete protection (no nausea [VAS < 5 mm], no vomiting, and no rescue medication) during the 120-504 hour window. (Definitions per protocol.) |
120-504 hours (Days 6-21) after ADC administration
|
|
Total Control (TC) Rate During the 120-504 Hour Window
Lasso di tempo: 120-504 hours (Days 6-21) after ADC administration
|
Proportion of participants achieving total control (no nausea [VAS = 0], no vomiting, and no rescue medication) during the 120-504 hour window. (Definitions per protocol.) |
120-504 hours (Days 6-21) after ADC administration
|
|
Antiemetic Efficacy Across Time Windows: No Nausea, No Significant Nausea, No Vomiting, CR, CP, TC, and Rescue Medication Rates
Lasso di tempo: Acute phase 0-24 h; delayed phase 24-120 h; overall 0-120 h; full course 0-504 h (Day 1-21)
|
For each of four time windows (0-24 h acute, 24-120 h delayed, 0-120 h overall, and 0-504 h full course [Day 1-21]), the following binary endpoints are assessed: no nausea rate (VAS < 5 mm), no significant nausea rate (VAS < 25 mm), no vomiting rate, complete response (CR) rate, complete protection (CP) rate, total control (TC) rate, and rescue medication use rate. The 0-120 h window reflects the period in which all three arms received identical baseline antiemetic prophylaxis (Days 1-5); by design no systematic between-arm difference is expected, and this window is used to verify the comparability of baseline efficacy and the internal consistency of the study. Missing-data handling is consistent with the primary endpoint. |
Acute phase 0-24 h; delayed phase 24-120 h; overall 0-120 h; full course 0-504 h (Day 1-21)
|
Collaboratori e investigatori
Sponsor
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Segni e sintomi, Digestivo
- Malattie della pelle
- Malattie del seno
- Condizioni patologiche, segni e sintomi
- Malattie della pelle e del tessuto connettivo
- Segni e sintomi
- Neoplasie mammarie
- Nausea
- Vomito
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Preparati farmaceutici
- Forme di dosaggio
- Composti policiclici
- Incinta
- In gravidanza
- Steroidi
- Composti anelli fusi
- Steroidi, fluorurati
- Incintadienetrioli
- Benzazepine
- Benzodiazepine
- Olanzapina
- Desametasone
- Compresse
- Netupitant, combinazione di farmaci Palosentron
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- 2610355-28
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .